In re BioClinica, Inc. Shareholder Litigation

more+
less-

In In re BioClinica, Inc. Shareholder Litigation, the Delaware Court of Chancery in a memorandum opinion on a motion to expedite examined the cumulative effect of deal protection devices to determine whether they should have been deemed preclusive under Omnicare.

The plaintiffs in BioClinica argued that the impact of a combination of (i) a standstill provision in the confidentiality agreement signed by a potential alternative bidder, which prevented that bidder from acquiring BioClinica other than through a tender offer, and (ii) a rights plan constituted an impermissible lock-up, because the announcement of a tender offer would trigger BioClinica’s poison pill.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Written by:

more+
less-

Morrison & Foerster LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×